Smith & Nephew Plc Additional Annual General Meeting update (8723I)

TIDMSN.

RNS Number : 8723I

Smith & Nephew Plc

06 April 2020

Smith+Nephew Additional Annual General Meeting update

6 April 2020

Further to the announcement made on 30 March 2020, Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces the following changes to the format of its Annual General Meeting (AGM) to be held at 2:00pm on Thursday, 9 April 2020.

In accordance with the Government's 'Stay at Home' measures and the closure of the AGM venue until further notice, the Board has resolved, in accordance with the Articles of Association of Smith & Nephew plc (the Company), that the AGM will be no longer be held at the venue stated in the Notice of Meeting dated 20 February 2020. The AGM will now be held at Sheethanger Common, Felden Lane, Felden, Hemel Hempstead, Hertfordshire, HP3 0BE at 2:00pm on Thursday, 9 April 2020.

Shareholders are reminded they must not attend the AGM, in line with the Government's 'Stay at Home' measures and travel restrictions.

Facilitated by the Company, the meeting will be convened with the minimum necessary quorum of two shareholders and will be chaired by Susan Swabey, Company Secretary. Susan is the registered holder of 30,770 ordinary shares of USD 0.20 each in the Company.

As previously announced, all valid proxy votes (whether submitted electronically or in hard copy form) will be included in the poll to be taken at the meeting.

There are no changes to the previously announced details of the Audiocast to be held at 3:00pm on Thursday, 9 April 2020 for registered shareholders and their corporate representatives or proxies.

Enquiries

Investors

   Andrew Swift                                                                  [phone] 

Smith+Nephew

Media

   Charles Reynolds                                                            [phone] 

Smith+Nephew

   Susan Gilchrist / Ayesha Bharmal                                    [phone] Brunswick 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter , LinkedIn , Instagram or Facebook .

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGMUPUMWCUPUUMQ

(END) Dow Jones Newswires

April 06, 2020 04:00 ET (08:00 GMT)